![]() |
Volumn 302, Issue 24, 2009, Pages 2697-2698
|
Strengthening institutional review board review of highly innovative interventions in clinical trials
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BLOOD SUBSTITUTE;
IMMUNOMODULATING AGENT;
MONOCLONAL ANTIBODY;
ADVISORY COMMITTEE;
CLINICAL TRIAL;
EXPERIMENTAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPOTENSION;
INSTITUTIONAL REVIEW;
MANDATORY REPORTING;
METHODOLOGY;
NATIONAL HEALTH ORGANIZATION;
NOTE;
PATIENT SAFETY;
PRIORITY JOURNAL;
PROTECTION;
TREATMENT OUTCOME;
ARTICLE;
DRUG TOXICITY;
ETHICS;
INTERPERSONAL COMMUNICATION;
PROFESSIONAL STANDARD;
RISK;
UNITED STATES;
UNIVERSITY HOSPITAL;
ACADEMIC MEDICAL CENTERS;
CLINICAL TRIALS AS TOPIC;
DISCLOSURE;
DRUG TOXICITY;
ETHICS COMMITTEES, RESEARCH;
HUMANS;
NATIONAL INSTITUTES OF HEALTH (U.S.);
RISK;
UNITED STATES;
|
EID: 73949149032
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2009.1917 Document Type: Note |
Times cited : (11)
|
References (10)
|